Project Grant HT94252311002
Award Date
9/1/23
Completion Date
8/31/27
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
The Department of the Army Medical Command awarded a $694,200 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research developing a novel therapeutic target in XP11.2 translocation renal cell carcinoma. The grant was awarded on July 1, 2022 under the Military Medical Research and Development program (CFDA 12.420), with a completion date of June 30, 2025. Through this funding, Dfci will conduct research to investigate medical solutions for renal cell...
The Department of the Army Medical Command awarded a $1,290,500 Project Grant to Dana-Farber Cancer Institute, Inc. to support research titled "CIRCULATING BIOMARKERS IN RENAL CELL CARCINOMA" under the Military Medical Research and Development program (CFDA 12.420). The four-year award beginning September 1, 2022 will fund research to investigate circulating biomarkers in renal cell carcinoma. The Military Medical Research and Development program aims to transform military and public...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
This federal Project Grant award, totaling $4,991,950.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding the "INVESTIGATION OF A MULTICANCER EARLY DETECTION TEST IN A HIGH-RISK MILITARY POPULATION" at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to develop and evaluate a novel multicancer early detection test for use within a high-risk military...
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $1,156,892 Project Grant from the Department of the Army Medical Command to utilize cell-free methylomes to inform clinical scenarios in renal cell carcinoma. The grant was awarded on August 15, 2021 with a completion date of August 14, 2024 under the Military Medical Research and Development program (CFDA 12.420). Through this funding, DFCI will apply its work on cell-free methylomes, a non-invasive method to analyze DNA methylation...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...